Brief: Pardes Biosciences Presents Interim Data From Phase 1 Trial Of Pbi-0451 As A Stand-Alone Oral Regimen For Covid-19
14/02/2022 12:35
Feb 14 (Reuters) - Pardes Biosciences Inc PRDS.O :
* PARDES BIOSCIENCES PRESENTS INTERIM CLINICAL DATA FROM
ONGOING
PBI-0451 PHASE 1 TRIAL SUPPORTING THE POTENTIAL OF PBI-0451 AS A
STAND-ALONE ORAL REGIMEN FOR COVID-19 AT CONFERENCE ON
RETROVIRUSES AND OPPORTUNISTIC INFECTIONS 2022
* PARDES BIOSCIENCES INC - PBI-0451 HAS BEEN GENERALLY
WELL-TOLERATED AND HAS SHOWN GOOD ORAL BIOAVAILABILITY
Source text for Eikon: ID:nGNX52Z6fD
Further company coverage: PRDS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pardes Biosciences
See all newsBrief: Pardes Biosciences Inc - Total Cash Amount That Medipacific Sub, Inc. Will Pay Pursuant To Terms Of Offer And Merger Agreement Is $2.13 Per Share
U.S. STOCKS ON THE MOVE-Argenx, ViewRay, Ford
Pardes Biosciences up on buyout deal with MediPacific
U.S. STOCKS ON THE MOVE-Activision Blizzard, Tesla, Paramount Global
Pardes Biosciences gains on buyout deal with MediPacific